Back
Sec.
40.129 What are the
MRO's functions in reviewing laboratory confirmed positive, adulterated,
substituted, or invalid drug test results?
(a) As the MRO, you must do the following with respect to
confirmed positive, adulterated, substituted, or invalid drug tests you
receive from a laboratory, before you verify the result and release it
to the DER:
(1) Review Copy 2 of the
CCF to determine if there are any fatal or correctable errors that may
require you to cancel the test (see Sec. Sec.
40.199 and 40.203). Staff under your direct, personal supervision
may conduct this administrative review for you, but only you may verify
or cancel a test.
(2) Review Copy 1 of the
CCF and ensure that it is consistent with the information contained on
Copy 2, that the test result is legible, and that the certifying
scientist signed the form. You are not required to review any other
documentation generated by the laboratory during their analysis or
handling of the specimen (e.g., the laboratory internal chain of
custody).
(3) If the copy of the documentation provided to you by the
collector or laboratory appears unclear, you must request that the
collector or laboratory send you a legible copy.
(4) Except in the
circumstances spelled out in Sec. 40.133
, conduct a verification interview. This interview must include direct
contact in person or by telephone between you and the employee. You may
initiate the verification process based on the laboratory results
report.
(5) Verify the test
result as either negative, positive, test cancelled, or refusal to test
because of adulteration or substitution, consistent with the
requirements of Sec. Sec. 40.135-40.145
and 40.159.
(b) Before you report a
verified negative, positive, test cancelled, refusal to test because of
adulteration or substitution, you must have in your possession the
following documents:
(1) Copy 2 of the CCF, a
legible copy of it, or any other CCF copy containing the employee's
signature; and
(2) A legible copy (fax,
photocopy, image) of Copy 1 of the CCF, containing the certifying
scientist's signature.
(c) With respect to
verified positive test results, place a check mark in the ``Positive''
box (Step 6) on Copy 2 of the CCF, indicate the drug(s)/ metabolite(s)
detected on the ``Remarks'' line, sign and date the verification
statement.
(d) If you cancel a
laboratory confirmed positive, adulterated, substituted, or invalid drug
test report, check the ``test cancelled'' box (Step 6) on Copy 2 of the
CCF, make appropriate annotation in the ``Remarks'' line, sign, provide
your name, and date the verification statement.
(e) Report the result in
a confidential manner (see Sec. Sec. 40.163-40.167
).
(f) With respect to
adulteration or substitution test results, check the ``refusal to test
because:'' box (Step 6) on Copy 2 of the CCF, check the ``Adulterated''
or ``Substituted'' box, as appropriate, make appropriate annotation in
the ``Remarks'' line, sign and date the verification statement.
(g) As the MRO, your
actions concerning reporting confirmed positive, adulterated, or
substituted results to the employer before you have completed the
verification process are also governed by the stand-down provisions of
Sec. 40.21.
(1) If an employer has a
stand-down policy that meets the requirements of Sec.
40.21 , you may report to the DER that you have received an
employee's laboratory confirmed positive, adulterated, or substituted
test result, consistent with the terms of the waiver the employer
received. You must not provide any further details about the test result
(e.g., the name of the drug involved).
(2) If the employer does
not have a stand-down policy that meets the requirements of Sec.
40.21 , you must not inform the employer that you have received
an employee's laboratory confirmed positive, adulterated, or substituted
test result until you verify the test result. For example, as an MRO
employed directly by a company, you must not tell anyone on the
company's staff or management that you have received an employee's
laboratory confirmed test result. [65
FR 79526, Dec. 19, 2000, as amended at 66 FR 41952, Aug. 9, 2001]
|